Andre Happe
Overview
Explore the profile of Andre Happe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Aridi L, Jantzem H, Happe A, Cauvin J, Carlhant-Kowalski D, Gourier G
Therapie
. 2025 Feb;
PMID: 40011171
Introduction: Spontaneous reporting is the reference method for collecting data on adverse drug reactions (ADRs). However, it remains insufficient. Text search in the electronic medical record has opened up a...
2.
Vo T, Gares V, Zhang L, Happe A, Oger E, Paquelet S, et al.
Stat Med
. 2023 Nov;
43(2):296-314.
PMID: 37985942
Record linkage is increasingly used, especially in medical studies, to combine data from different databases that refer to the same entities. The linked data can bring analysts novel and valuable...
3.
Bonnet P, Gal S, Gautier C, Hoffmann C, Le Nan N, Happe A, et al.
Antimicrob Agents Chemother
. 2022 Nov;
66(12):e0099022.
PMID: 36317930
Pneumocystis jirovecii infections occur in patients treated with methotrexate (MTX) because of immunosuppressive effects of this highly potent dihydrofolate reductase (DHFR) inhibitor. Conversely, MTX may act as an anti drug...
4.
Oger E, Kerbrat S, Nowak E, Paillard F, Scarabin P, Happe A
J Clin Hypertens (Greenwich)
. 2022 Mar;
24(4):438-448.
PMID: 35229448
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) both inhibit the renin-angiotensin system (RAS) but have different sites of action. Whether clinically meaningful differences exist is still debated....
5.
Scailteux L, Despas F, Balusson F, Campillo-Gimenez B, Mathieu R, Vincendeau S, et al.
Br J Clin Pharmacol
. 2021 Jul;
88(1):336-346.
PMID: 34224605
Aims: Safety profiles of abiraterone and enzalutamide rely mainly on Phase III clinical trials. Our objective was to estimate the incidence rate ratio (IRR) for certain adverse events leading in...
6.
Cattelain-Lopez E, Chu Miow Lin D, Happe A, Goupille P, Oger E, Mulleman D
Joint Bone Spine
. 2021 Jan;
88(2):105121.
PMID: 33485155
No abstract available.
7.
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017
Poizeau F, Kerbrat S, Happe A, Rault C, Drezen E, Balusson F, et al.
J Invest Dermatol
. 2020 Oct;
141(4):830-839.e3.
PMID: 33049268
Immune checkpoint inhibitors and targeted therapies have profoundly altered the management of several cancers over the past decade. Metastatic melanoma has been at the forefront of these changes. We provide...
8.
Scailteux L, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, et al.
Am J Epidemiol
. 2020 Sep;
190(3):413-422.
PMID: 32944756
Abiraterone acetate (ABI) and enzalutamide (ENZ) are considered to be clinically relevant comparators among chemotherapy-naive patients with castration-resistant prostate cancer. No clinical trials comparing overall survival with ABI versus ENZ...
9.
Poizeau F, Nowak E, Kerbrat S, Le Nautout B, Droitcourt C, Drici M, et al.
JAMA Dermatol
. 2020 Sep;
156(11):1208-1215.
PMID: 32902568
Importance: Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe psoriasis, psoriatic arthritis, and Crohn disease. In 2011, a meta-analysis of randomized...
10.
Droitcourt C, Nowak E, Rault C, Happe A, Le Nautout B, Kerbrat S, et al.
Int J Epidemiol
. 2019 May;
48(5):1623-1635.
PMID: 31098637
Background: Isotretinoin is the only effective treatment for severe acne. An isotretinoin-related suicide risk is still debated and under scrutiny by regulatory agencies. Our objectives were: to assess the risk...